Oncogenes in ovarian cancer

Hematol Oncol Clin North Am. 1992 Aug;6(4):813-27.

Abstract

The discovery of cancer-causing genes has provided us with the exciting opportunity to begin to understand the molecular pathology of ovarian cancer. Activation of several of these genes including HER-2/neu, myc, ras, and p53 has been described in some ovarian cancers (Table 2). In addition, some proto-oncogenes such as the EGF receptor (erbB) and the M-CSF receptor (fms) are expressed along with their respective ligands in some ovarian cancers. Finally, for every oncogene that has been studied in ovarian cancer, there are at least a half-dozen that remain unexplored. In the future, when we have a better understanding of the molecular pathology involved in the development of ovarian cancer, this may allow us to better diagnose and treat, and eventually prevent, ovarian cancer.

Publication types

  • Review

MeSH terms

  • Female
  • GTP-Binding Proteins / physiology
  • Genes, Tumor Suppressor
  • Humans
  • Oncogenes*
  • Ovarian Neoplasms / enzymology
  • Ovarian Neoplasms / genetics*
  • Protein-Tyrosine Kinases / physiology

Substances

  • Protein-Tyrosine Kinases
  • GTP-Binding Proteins